ongoing

DO-IT is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) trial, evaluating the safety and efficacy of intravenous thrombolysis (IVT) in patients with an acute ischemic stroke (AIS) and recent intake of direct oral anticoagulants (DOACs). 906 patients will be randomly assigned to either the standard or the experimental arm with a ratio of 1:1 (453 patients per group). In the experimental arm, patients will receive IVT with alteplase or tenecteplase plus best medical treatment (BMT). In the standard arm, patients will receive BMT.

doit-trial.ch – DO-IT – The DOAC Intravenous Thrombolysis trial

Study Type

Phase IV

Study Design

A multicenter (up to 100 sites), prospective, two-arm, randomized (1:1), open label, blinded endpoint (PROBE) superiority trial

NO. of Countries

15

NO. of Sites

100

NO. of Participants

906

Study Period

2025-2029

Sponsor

Inselspital (University Hospital) Bern

Canadian Institutes of Health Research

Back To Top